文献速递其他结缔组织病

皮肌炎患者对静脉注射免疫球蛋白应答的预测因素:ProDERM研究

Predictors of response to intravenous immunoglobulin in patients with dermatomyositis: the ProDERM study.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

ProDERM研究为前瞻性随机安慰剂对照3期试验,纳入95例皮肌炎患者,第0–16周每4周接受2.0 g/kg静脉注射免疫球蛋白(Octagam,10%)或安慰剂,随后开放标签延展至第40周。分析显示,无论人口学特征和多数自身抗体状态如何,静脉注射免疫球蛋白均有效;皮肤疾病活动度较高和/或抗TIF1-γ抗体者应答最佳,肺部疾病活动度预测应答较低但仍有效,需进一步研究。

要点

  • 第16周或第40周总改善评分与年龄、性别、族裔、病程/活动度及既往用药无关。
  • 多变量分析示MDAAT皮肤评分较高者至少达到最小总改善评分改善的机会更好。
  • 抗TIF1-γ抗体者总改善评分应答更好,但控制皮肤活动度后抗体分类与疗效无显著关联。

核心结论

  • 静脉注射免疫球蛋白治疗皮肌炎有效,不受人口学特征和多数自身抗体状态影响。
  • 皮肤疾病活动度较高和/或抗TIF1-γ抗体者应答最佳,肺部疾病活动度预测应答较低但仍有效,需进一步研究。

研究设计与样本

  • ProDERM为前瞻性、随机、安慰剂对照3期研究,纳入95例皮肌炎患者。
  • 第0–16周每4周给予2.0 g/kg静脉注射免疫球蛋白(Octagam,10%)或安慰剂,随后开放标签延展至第40周,所有患者接受静脉注射免疫球蛋白。
  • 采用单变量和多变量分析评估基线变量与总改善评分的关联,包括肌炎疾病活动度评估工具(MDAAT)及肌炎特异性和肌炎相关性自身抗体。

主要发现

  • 单变量分析未发现第16周或第40周总改善评分与年龄、性别、族裔、病程/活动度、皮肤/骨骼/胃肠道/肌肉疾病活动度或既往失败或合并用药有显著关联。
  • 多变量分析发现MDAAT皮肤评分较高的患者至少达到最小总改善评分改善的机会更好。
  • MDAAT肺部评分较高与较低但仍相当可观的改善机会相关。
  • 抗TIF1-γ抗体患者总改善评分应答更好;但控制皮肤疾病活动度后,抗体分类(包括抗TIF1-γ)与疗效结局无显著关联。

局限性

  • 原文结论指出肺部疾病活动度预测较低但仍有效的静脉注射免疫球蛋白应答,需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The phase 3 ProDERM study demonstrated intravenous immunoglobulin (IVIg) was safe and effective in patients with dermatomyositis (DM). This analysis assessed clinical and serological predictors of IVIg response in DM patients from ProDERM. METHODS: ProDERM was a prospective, randomized, placebo-controlled study of DM patients. For weeks 0-16, patients received 2.0 g/kg IVIg (Octagam, 10%) or placebo every 4 weeks. Eligible patients entered the open-label extension phase, where all received IVIg to week 40. Univariate and multivariate analyses examined associations between baseline variables and total improvement score (TIS), including myositis disease activity assessment tool (MDAAT; assessing different organ involvement), and myositis-specific and myositis-associated autoantibodies. RESULTS: Ninety-five patients were enrolled. Univariate analyses found no significant association between TIS at week 16 or 40 and age; sex; ethnicity; disease duration/activity; cutaneous, skeletal, gastrointestinal or muscle disease activity; or previous failed or concomitant medications. Multivariate analysis found patients with higher MDAAT cutaneous scores had a better chance of at least minimal TIS improvement. Higher MDAAT pulmonary scores were associated with a lower, but still considerable, chance of improvement. Patients with TIF1-γ antibodies had a better TIS response; however, after controlling for cutaneous disease activity, there was no significant association between antibody classification (including anti-TIF1-γ) and efficacy outcome. CONCLUSION: IVIg was effective in treating DM patients regardless of demographic features and autoantibody status (for most autoantibodies). Patients with higher cutaneous disease activity and/or anti-TIF1-γ responded best to IVIg, while pulmonary disease activity predicted a lower, but still effective, IVIg response, warranting further investigation. TRIAL REGISTRATION: ClinicalTrials.gov, http://clinicaltrials.gov, NCT02728752.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Charles-Schoeman C, Schessl J, Bata-Csörgő Z, et al. Predictors of response to intravenous immunoglobulin in patients with dermatomyositis: the ProDERM study. Rheumatology (Oxford). 2025. PMID: 39918968. doi:10.1093/rheumatology/keaf070

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。